Zhi Peng

14PUBLICATIONS
69CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsImmunogenetics (incl. genetic immunology)Oncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Sep 24, 2026
First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT).

|Jun 04, 2026
Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

|Jun 01, 2026
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

|Mar 12, 2026
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Zhi Peng, Yanqiao Zhang, Huiting Xu

|Mar 04, 2026
Allogeneic B7-H3-Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study.

Chang Liu, Jiarui Li, Dan Liu

|Oct 07, 2025
Tumors with microsatellite instability upregulate TREX1 to escape antitumor immunity.

Yan Xu, Zheqi Zhou, Wenzheng Chen

Pageof 3

Frequent Collaborators

3 joint publications

Lin Shen

3 joint publications

Lin Shen

2 joint publications

Jian Li

2 joint publications

Panpan Zhang